Prevalence and effect of bacterial co-infections on clinical outcomes in hospitalized COVID-19 patients at a tertiary care centre of India

Introduction

The human race has witnessed the emergence of four severe viral outbreaks in the last two decades: the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) epidemic in 2002, the influenza A H1N1 pandemic in 2012, Middle East Respiratory Syndrome (MERS) outbreak in 2009 and most recently the COVID-19 pandemic [1]. COVID-19 has emerged as a global pandemic affecting millions of people world-wide and is proving to be a greater danger than MERS and SARS Coronaviruses [2]. A plethora of symptoms have been described in the past few months, clearly indicating that COVID-19 is a complex disease, which in no way consists only of a respiratory infection. It presents with a variety of unspecific symptoms so that the differential diagnosis encompasses a wide range of infections.Most common symptoms of COVID-19 include respiratory symptoms like cough, sputum, shortness of breath, fever; musculoskeletal symptoms like myalgia, joint pain, headache, fatigue; enteric symptoms like abdominal pain, vomiting, diarrhea and mucocutaneous symptoms (less common) [3]. Lung infections may progress in a few cases to ARDS (Acute respiratory distress syndrome), shock and death. Cytokine storm, immune dysregulation and various viral evasion mechanisms in the presence of various co-morbid conditions has contributed to fatal outcomes in the COVID-19 patients [4].

Super-infection with bacterial pathogens has been identified in various viral respiratory illnesses in the past and contributed to significant rates of morbidity and mortality [5–7]. Mortality has been reported to be as high as 20-30% in such cases of super-infection [7, 8]. Existence of bacterial co-pathogens in such respiratory patients leads to increased hospital stay, greater chances of acquiring nosocomial infections and overall increase in cost of hospital stay [9]. SARS-CoV-2 is a new virus with still limited knowledge about its pathogenesis and clinical manifestations. Hence, there are several areas of knowledge gap regarding this novel Coronavirus. One such area of potential research and studies is about the co-existence, prevalence and incidence of bacterial pathogens in SARS-CoV-2[10, 11]. Various anti-viral and immuno-modulatory agents are being tried in COVID-19 hospitalized patients, and several others are in experimental phase and under trials. Antibiotics are of no use in such patients but are routinely prescribed due to the potential risk of secondary bacterial infections [10]. Various studies have advocated the use of antibiotics in patients suffering from respiratory symptoms of COVID-19 [12, 13]. However, such irrational and unguided antibiotic use ultimately leads to emergence of antimicrobial resistance [11].

Hence, there is a dire need to study bacterial co-infections in COVID-19 patients and understand the exact prevalence of such co-pathogens for the proper and rational use of antibiotics. This study was planned with the aim to study the prevalence, demographic parameters, risk factors, antibiotic sensitivity patterns and outcomes in hospitalized COVID-19 patients with bacterial co-infections.

Material and Methods

Results

A total of 1019 patients tested positive for COVID-19 in a span of six months and were hospitalized at our COVID hospital. Out of these hospitalized COVID-19 patients, 5.2% (n=53/1019) showed clinical signs of bacterial co-infection. Out of the total number of patients having confirmed diagnosis of bacterial co-infection, a majority (66%; n=35/53) acquired infections in the hospital (>48 hours of admission). The mean age of the patients was 68 years (SD=57 ± 16) and it ranged from 8-75 years. Males comprised the majority of the cases (61 %; n=32/53) as compared to females. Various co-morbidities in the patients were also studied; hypertension (61%; n= 32/53) and diabetes mellitus (58%; n=31/53) emerged as the most prevalent medical conditions. COPD/Asthma (27%; n=14/53), chronic kidney disease (CKD) (23%; n=12/53) and chronic liver diseases (CLD) (19%; n=10/53) were the other major co-morbidities among the COVID-19 patients.

Antibiotic sensitivity profile of bacterial isolates

Antibiotic sensitivity testing revealed colistin (99%), imipenem (78%) and fosfomycin (95%) (only in urinary isolates) as the most effective drugs against Gram-negative isolates whereas vancomycin (100%), teicoplanin (99%) and doxycycline (71%) emerged as the most potent drugs for Gram-positive bacterial infections. Detailed antibiotic sensitivity patterns for both Gram-negative and Gram-positive isolates are summarized in Fig 1 & 2 respectively.

• Download figure
• Open in new tab

Fig 1:

Antibiotic sensitivity pattern in Gram-negative isolates.

• Download figure
• Open in new tab

Fig 2:

Antibiotic sensitivity pattern in Gram-positive isolates.

Antibiotic usage

As per the WHO criteria of AWaRe class of antibiotics, maximum antibiotics were prescribed from the “watch” (48.02 %) and “reserve” categories (24.21 %). Only 20.7 % were given antibiotics from the “access” category while 7.07 % of the patients were not recommended any antibiotics as depicted in Fig 3 A & B.

• Download figure
• Open in new tab

Fig 3:

Illustration of antibiotics as per WHO Aware, Watch and Reserve (AWaRe) classification. (A) Total antibiotics usage in %. (B) Class of antibiotics usage in %.

Discussion

SARS CoV-2 is a newly emerging virus which has led to a global pandemic in a span of only a few months. Its immunology, pathogenesis, clinical features and implications on the health care settings are yet to be fully understood. There is a lack of clinical research and data on the bacterial infections in these COVID-19 patients. Our study reported a bacterial co-infection rate of 5.2 % which is very well in agreement to other similar studies done in various parts of the world. A case series from Washington reported bacterial co-infection rate as 4.8%; while some studies from China also reported a rate of 5-9% [18–24]. A meta-analysis done by Lansbury et al., reported a bacterial co-infection rate of around 6.8% in hospitalized COVID-19 cases [25].

The current study stressed the prevalence of bacterial co-infections to be higher among the elderly age group (>65years). Several studies have emphasized the point of enhanced pathogenesis of COVID-19 in the elderly age group. A lot of factors like decreased mucociliary clearance, ciliary ultrastructural anomalies and immunosenescence play a key role in this. “Inflamm-aeging “or increased release of inflammatory mediators and cytokines leading to a cytokine surge is involved in tissue damage and multi-organ failure in such patients [26]. A higher proportion of co-morbidities like diabetes and hypertension were seen in the COVID cases in our study. This can be supported by the fact that diabetes mellitus itself down-regulates the immune system by decreasing the effective T-cell and neutrophils response [27]. It causes decreased phagocytosis, ineffective chemotaxis and decreased killing of invading microbes by neutrophils and macrophages leading to increased susceptibility to secondary bacterial infection [28]. Our study however failed to show any statistical significance for the association of various co-morbidities to the increase in bacterial co-infection rates among the COVID-19 cases. As such no role of increase in bacterial co-infection rates per se have been described so far in this sub-group of patients.

Extensive search of literature revealed that there is no available report of high rate of bacteremia and concurrent urinary tract infection (UTI) in COVID-19 patients. Ours is first such study revealing bacteremia (37%) and UTIs (31%) as the most common co-infections in COVID-19 patients. Other isolates were also isolated from respiratory (28%) and pus/aspirate (4%) samples in the current study. E. coli, Klebsiella and Pseudomonas were the predominant Gram-negative pathogens. One similar study in COVID-19 patients reported UTI in almost half of the patients (57%) [29]. It also reported E. coli and Enterobacter cloacae as the most commonly isolated pathogens. Another study by Lansbury et al., reported respiratory pathogens such as Mycoplasma pneumoniae, P. aeruginosa, and Haemophilus influenza as the most common isolates [25]. Increased prevalence of Gram-negative as well as Gram-positive pathogens in the current study can be attributed to the immune dysregulation leading to nosocomial infections and gut dysbiosis in COVID-19 positive patients. The inflammatory mediators disrupt the intestinal permeability leading to the leakage of gut microbes and associated metabolites into circulation. The leaked microbes and products via circulation migrate to organs including lungs and produce bacteremia, UTIs and various other infections [30]. Higher rates of diabetes in our group of patients also predispose to increase in secondary bacterial infections including UTIs [31]. Immune dysregulation in SARS-CoV-2 infection is characterized by lymphopenia, increased neutrophil–lymphocyte ratio, decreased NK-cells and CD8+T-cell activity, decreased regulatory T-cells and increased CD4+ to CD8+ ratio. Failure to eliminate virus due to inappropriate IFN response and decreased number and function of CD8+ and NK-cells further leads to virus induced tissue damage and makes the body more prone to secondary bacterial infections [31].

Colistin, Fosfomycin and Vancomycin proved to be some very effective drugs in treating bacterial infections in COVID-19 positive cases. Administration of antibiotics in this co-infection sub-group is vital to combat the ongoing bacterial infection in the form of blood stream, urinary and respiratory infections as well as to avoid the increased chances of acquiring secondary bacterial infections in such co-morbid patients. There was no significant past history of any antibiotic or antimicrobial usage in these groups of patients. Providing the correct and narrowed antibiotic coverage through proper antibiotic sensitivity testing will look after the ill effects caused by broader empiric treatment in such cases. As already highlighted in the study, most antibiotics prescribed were from the “watch” and “reserve” categories of WHO AWaRe classification. Antibiotic stewardship programmes will lead the path towards righteous treatment in COVID-19 infection group and will prevent the after effects of long term treatment.

Discussing the clinical outcomes of our study, we noticed a much higher rate of in-patient mortality in bacterial co-infection COVID-19 group (39%) as compared to the no infection group (17%). A similar study by Alvaro et al., reported a mortality rate of 50% in COVID-19 patients with concomitant bacterial infection [29]. While a study from Wuhan, China also reported similar mortality rates in this group of patients [20]. The increase in mortality rates may also be attributed to the older population involved with bacterial co-infections along with presence of other co-morbidities [32, 33]. The older population has weakened immune system due to immunosenescence and hence succumbs to the infections more easily than the younger ones. These people, therefore, more likely require interventions in the form of intubation, mechanical ventilation and use of vasopressive drugs to improve the outcome and increase their life expectancy. This fact was strongly suggested by our study where we noticed statistical significance in these COVID-19 cases with bacterial co-infection for the use of ventilator support, intubation and use of vasopressors as compared to the no infection group.

A lot of aspects still need to be explored in the current COVID-19 pandemic situation for the better understanding of its pathogenesis and control. Bacterial co-infections not necessarily but certainly may increase the mortality rates in COVID-19 positive patients. Antibiotic prescription as well as usage in this current situation must be properly guided through proper culture reports, sensitivity testing and stringent antibiotic stewardship programmes.

Declarations